Best Overall Response-Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE.

Jiangang Liu David S Moura Robin L Jones Amit Aggarwal Philip J Ebert Andrew J Wagner Jennifer Wright Javier Martín-Broto William D Tap

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

The refined REDSARC signature provides a potential tool to direct the application of doxorubicin in sarcomas and other malignancies. Validation and further refinement of the signature in other potentially subtype specific prospective cohorts is recommended.

Keyphrases

soft tissue
drug delivery
high grade
cancer therapy
climate change